The impact of neoadjuvant chemotherapy on immunohistochemistry and molecular subtype in breast cancer: A retrospective analysis from Oman
Qatar Medical Journal · 2026 · 2026 (1)
DOI: 10.5339/qmj.2026.3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Qatar Medical Journal, 2026. Verfasst von Mustafa Talib Al-Ani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Sultan Qaboos Comprehensive Cancer Care and Research Centre, University Medical City, Oman. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Neoadjuvant chemotherapy (NACT) is used in breast cancer (BC) to downsize and downstage the tumor before surgery. Different studies were conducted looking into the alterations in the immunohistochemistry after NACT, which may alter the adjuvant treatment. Our study aimed to assess the changes in immunohistochemistry biomarker status (estrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor 2 [HER2]) in BC cells after administration of NACT at a single institution in Oman.
Methods
We conducted a retrospective cross-sectional study on patients with BC with residual disease post-NACT in a single institution and studied immunohistochemistry status changes before and after NACT. We used the McNemar test to evaluate the receptor changes, and logistic regression to assess the effect of risk factors on receptor status change.
Results
All biomarkers changed after NACT, with a tendency for BC cells to lose PR and HER2 expression and gain ER expression. The immunohistochemistry changes were 36/114 (31.6%) in PR, 7/114 (6.1%) in ER, and 11/114 (9.6%) in HER2. BC subtypes changed in 4/114 (3.5%) of HER2+ve, 10/114 (8.8%) of hormone positive (ER or PR) with HER2 overexpression (HER2+ve/HR+ve), 3/114 (2.6%) in hormone positive with HER2 negative (HR+ve), and 3/114 (2.6%) triple-negative BCs. These changes resulted in adjuvant treatment adjustments in 9/110 (8.18%) patients with residual disease.
Conclusion
Changes in the expression of all immunohistochemistry biomarkers and BC subtypes occurred after NACT, which led to changes in adjuvant treatment in specific cases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Sultan Qaboos Comprehensive Cancer Care and Research Centre, University Medical City, Oman.
- Research Laboratories Department, Sultan Qaboos Comprehensive Cancer Care and Research Centre, University Medical City, Oman.
- Department of Medicine, Sultan Qaboos Comprehensive Cancer Care and Research Centre, University Medical City, Oman.
- Department of Pathology, Sultan Qaboos Comprehensive Cancer Care and Research Centre, University Medical City, Oman *Email: mustafa.talib.2@gmail.com.
Zitieren
APA
Al-Ani, M. T., Ismaili, A. R. A., Al-Mahrouqi, N., Al-Sayegh, H., Baimani, K. A., Alshahi, H. S. A., Trehan, A., Al-Ishaq, Z., Youssef, M., Nadaf, A. N., & Alajmi, A. A. (2026). The impact of neoadjuvant chemotherapy on immunohistochemistry and molecular subtype in breast cancer: A retrospective analysis from Oman. Qatar Medical Journal, 2026(1). https://doi.org/10.5339/qmj.2026.3
Vancouver
Al-Ani MT, Ismaili ARA, Al-Mahrouqi N, Al-Sayegh H, Baimani KA, Alshahi HSA, et al. The impact of neoadjuvant chemotherapy on immunohistochemistry and molecular subtype in breast cancer: A retrospective analysis from Oman. Qatar Medical Journal. 2026;2026(1). doi:10.5339/qmj.2026.3
BibTeX
@article{AlAni2026,
author = {Al-Ani, Mustafa Talib and Ismaili, Asila Rashid Al and Al-Mahrouqi, Nahad and Al-Sayegh, Hasan and Baimani, Khalid Al and Alshahi, Hind Saif Ali and Trehan, Arti and Al-Ishaq, Zaid and Youssef, Marwa and Nadaf, Asma Naaz and Alajmi, Adil Aljarrah},
title = {The impact of neoadjuvant chemotherapy on immunohistochemistry and molecular subtype in breast cancer: A retrospective analysis from Oman},
journal = {Qatar Medical Journal},
year = {2026},
volume = {2026},
number = {1},
doi = {10.5339/qmj.2026.3}
}
EUVIMED